Get Ready Alnylam plus CDXS making the turn this is a disruptive technology that has 7 contracts in the works some with the largest sIRna drug companies in the world. CDXS & ALNY founder both on CDXS executive board and both know the imperative Enzymatic manufacturing is for the future cleaner drugs and higher Yield+ Purity than phosphate chemistry doesn't make economic sense for these companies. 450 SirNA drugs in the pipeline close to 50 Late stage that could treat millions tens of millions or even hundreds of millions of people! Alnylam Platform Innovation Will Drive the RNAi Revolution into the Future
Alnylam will strive to continue to provide best-in-class delivery solutions as it extends the applications for RNAi therapeutics. The Company’s vision is to unlock every major tissue for RNAi therapeutics by 2030. Alnylam scientists will present new preclinical data on delivery solutions with best-in-class potential for adipose, muscle, heart, and kidney tissue. The Company will also share an update on its approach to crossing the blood-brain barrier, as well as emerging technology to enable combination therapy and innovation in manufacturing with enzymatic ligation. Enzymatic ligation has the potential to revolutionize the manufacturing of RNAi therapeutics to meet growing demand and improve efficiency.
https://investors.alnylam.com/press-release?id=28716 CDXS will be the leader in enzymatic ligation/ enzymatic manufacturing for these drugs and other classes of new medicines thats why opal eye the top 3 rated firm in biotech keeps buying
Market Data 
Markets 
AI
